Log in to search using one of your social media accounts:

 

High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients

ConclusionsThe overall frequencies of theBRCA germline mutations were 10.2% in breast and 30.7% in ovarian cancer patients. These data shed new light into the prevalence ofBRCA mutations in the Arab women population.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research

Related Links:

Purpose of review The recent United States Food and Drug Administration approvals of niraparib and olaparib as maintenance monotherapy for platinum-sensitive, high-grade ovarian cancers independent of BRCA status reflect a willingness to seek indications for poly-ADP-ribose polymerase (PARP) inhibitors beyond cancers with deleterious breast cancer 1 and breast cancer 2 mutations. In this review, I describe the rationale behind current PARP combination clinical trials with chemotherapies, angiogenesis inhibitors, cell cycle checkpoint inhibitors, and inhibitors of the phosphoinositide 3-kinase/AK thymoma/mechanistic targe...
Source: Current Opinion in Obstetrics and Gynecology - Category: OBGYN Tags: GYNECOLOGIC ONCOLOGY: Edited by Gottfried E. Konecny Source Type: research
AbstractHereditary breast and ovarian cancer (HBOC) syndrome represents 5 −10% of all breast cancers. In Japan, the HBOC syndrome is frequently diagnosed in patients with breast cancer. Therefore, a treatment strategy combining a plan for existing breast cancer and for reduction of future breast and ovarian cancer risk is necessary. Breast cancer risk-reducing managemen t involves three options—surveillance, chemoprevention, and risk-reducing mastectomy (RRM). RRM can prevent>90% of new breast cancers. Ovarian cancer risk management options are more limited, and risk-reduction salpingo-oophorectomy is the on...
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
In conclusion, we demonstrated that dual CDK + PARP inhibition is synthetic lethal in both BRCA wild-type and mutant TNBC cell lines and is dependent upon down regulation of c-myc. This study supports c-myc as predictor of response to PARP inhibitor therapy and may also serve as a biomarker of response to Dinaciclib + PARPi therapy in high MYC expressing tumors.Citation Format: Jason PW Carey, Smruthi Vjayaraghavan, Kelly Hunt, Khandan Keyomarsi. Downregulation of c-myc is synthetic lethal with PARP inhibitors in high MYC cancers independent of BRCA status [abstract]. In: Proceedings of the AACR Precision Medicine Series: ...
Source: Molecular Cancer Therapeutics - Category: Cancer & Oncology Authors: Tags: Finding Synthetic Lethal Interactions through Functional Genomics: Poster Presentations - Proffered Abstracts Source Type: research
One typical mechanism to promote genomic instability, a hallmark of cancer, is to inactivate tumor suppressors, such as PALB2. It has recently been reported that mutations in PALB2 increase the risk of breast cancer by 8-9 fold. PALB2 was identified BRCA2 interacting protein, essential for BRCA2 anchorage to nuclear structures and for its function in double-strand break repair. Inherited mutations in PALB2 are associated with a predisposition for ovarian, breast and pancreatic cancers. The basis of the tumorigenic potential of PALB2 is thought to be related to functions in homologous recombination. Therefore, the regulatio...
Source: Molecular Cancer Therapeutics - Category: Cancer & Oncology Authors: Tags: Finding Synthetic Lethal Interactions through Functional Genomics: Poster Presentations - Proffered Abstracts Source Type: research
Deleterious mutations in DNA repair pathways, including breast-cancer susceptibility gene 1 (BRCA1) and breast-cancer susceptibility gene 2 (BRCA2) mutation carries, predispose to an elevated risk for several familial tumor types, such as ovarian cancer (OC), breast cancer and prostate cancer [1 –3].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Controversy Source Type: research
Mutation in BRCA1 and BRCA2 genes are associated with an increased risk for developing breast and ovarian cancer. Controversy exists about ovarian reserve and fertility in BRCA mutation carriers. Studies suggest that these patients may have low ovarian reserve and poor response to ovarian stimulation. The impaired ability of the mutated BRCA gene to repair double-strand breaks in DNA may prompt oocyte aging, apoptosis and meiotic errors. In vitro maturation (IVM) of cumulo-oocyte complexes (COC) retrieved at germinal vesicle stage, followed by vitrification of metaphase 2 oocytes, has recently emerged as an option for youn...
Source: Fertility and Sterility - Category: Reproduction Medicine Authors: Tags: Oral session Source Type: research
Dante Labs offered me their BRCA genetic test, which I gladly accepted as I never had an evaluation focused on my BRCA1 and BRCA2 genes. These are very important as their mutations increase the risk of breast cancer and ovarian cancer in women, and prostate cancer in men. Here is my verdict. The Angelina effect and why BRCA genes matter The concept and practice of BRCA genetic testing became extremely popular after Hollywood actress Angelina Jolie publicized her results in 2013 alongside her decision to undergo a double mastectomy. A merciless but effective way to avoid getting breast cancer. Researchers even found t...
Source: The Medical Futurist - Category: Information Technology Authors: Tags: Genomics cancer gc3 genes Genetic testing genetics Health Healthcare Innovation personalized genetics Personalized medicine Source Type: blogs
In patients with HER2-negative (human epidermal growth factor receptor type 2) metastatic breast cancer and a germlineBRCA mutation, olaparib monotherapy significantly improved progression-free survival compared with standard single-agent chemotherapy. Reported in theNew England Journal of Medicine, the phase 3trial is the first in which a poly(adenosine diphosphate –ribose) polymerase (PARP) inhibitor has shown a significant benefit other than for patients with ovarian cancer. PARP inhibitors interfere with DNA repair in cancer cells, leading to cancer cell death.
Source: JAMA - Category: General Medicine Source Type: research
Conclusion: Inconsistent with previous meta-analysis, this meta-analysis shows that the XRCC2 rs3218536 polymorphism was associated with breast and ovarian cancer risk in overall population, especially among Caucasians. PMID: 28749098 [PubMed - as supplied by publisher]
Source: Asian Pacific Journal of Cancer Prevention - Category: Cancer & Oncology Tags: Asian Pac J Cancer Prev Source Type: research
AbstractPurpose of ReviewBreast cancer treatment continues to evolve as targeted therapeutic strategies are developed for the various molecular subtypes of breast cancer. The PARP inhibitors represent a novel targeted therapy for tumors with defective homologous recombination DNA repair. These agents may become standard new treatment options for patients harboring BRCA1/2 mutations and show promise in BRCA1/2 wild-type patients with triple-negative breast cancers, which are treated predominantly with traditional cytotoxic chemotherapy. This review will discuss the results of clinical trials of these agents in breast cancer...
Source: Current Breast Cancer Reports - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Gastroschisis Repair | Genetics | Middle East Health | Ovarian Cancer | Ovaries | Women